ReviewWorld journal of gastroenterology2014
Histopathology of hepatocellular carcinoma.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed.
- Counterfactual Diffusion Models Provide Interpretable Explanations of Artificial Intelligence Models in Pathology.Cancer research · 2026Article
- Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions.Liver research (Beijing, China) · 2026Review
- A novel hypoxia-related signature for predicting prognosis, immune characteristics, and therapeutic response in hepatocellular carcinoma.Discover oncology · 2026Article
- Predicting early progression to atezolizumab-bevacizumab in hepatocellular carcinoma: a clinical and imaging-based scoring system.European radiology · 2026Article
- Label-free multiphoton microscopy and machine learning for recognition of hepatocellular carcinoma.Scientific reports · 2026Article
- Modeling hepatic fibrosis in TP53 knockout iPSC-derived human liver organoids.Molecular oncology · 2026Article
- Article
- Article
- Beyond bones: Revisiting the role of vitamin D in chronic liver disease.World journal of hepatology · 2025Review
- Counterfactual Diffusion Models for Interpretable Morphology-based Explanations of Artificial Intelligence Models in Pathology.bioRxiv : the preprint server for biology · 2025Article
- Silibinin-Conjugated Galactose Dendrimers for Targeted Treatment of Hepatocellular Carcinoma.ACS applied materials & interfaces · 2025Article
- Distinguishing Hepatocellular Carcinoma from Cirrhotic Regenerative Nodules Using MR Cytometry.Cancers · 2025Article
- Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications.Radiology and oncology · 2025Review
- The association between Clonorchis sinensis seropositivity and hepatocellular carcinoma in an endemic area: a study in Guangxi, China.BMC infectious diseases · 2025Article
- Clinicopathological Study on Morphological Subtypes of Hepatocellular Carcinoma: A Single Tertiary Referral Center Experience.Cancer reports (Hoboken, N.J.) · 2025Article
- Synchronous Hepatocellular and Intrahepatic Cholangiocellular Carcinoma With Predominant Ductal Plate Malformation Pattern. A Case Report and Review of the Literature.Cancer reports (Hoboken, N.J.) · 2025Review
- Fluorescence lifetime imaging microscopy approach reveals quantitative signatures for hepatocellular carcinoma diagnosis.Frontiers in oncology · 2025Article
- Ameliorative effects of Turbinaria ornata extract on hepatocellular carcinoma induced by diethylnitrosamine in-vivo.Journal of molecular histology · 2024Article
- Review
- Comparing CD10 Expression With the Clinicopathological Features and Hormone Status of Invasive Breast Cancer.Cureus · 2024Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is currently the sixth most common type of cancer with a high mortality rate and an increasing incidence worldwide. Its etiology is usually linked to environmental, dietary or life-style factors. HCC most commonly arises in a cirrhotic liver but interestingly an increasing proportion of HCCs develop in the non-fibrotic or minimal fibrotic liver and a shift in the underlying etiology can be observed. Although this process is yet to be completely understood, this changing scenario also has impact on the material seen by pathologists, presenting them with new diagnostic dilemmas. Histopathologic criteria for diagnosing classical, progressed HCC are well established and known, but with an increase in detection of small and early HCCs due to routine screening programs, the diagnosis of these small lesions in core needle biopsies poses a difficult challenge. These lesions can be far more difficult to distinguish from one another than progressed HCC, which is usually a clear cut hematoxylin and eosin diagnosis. Furthermore lesions thought to derive from progenitor cells have recently been reclassified in the WHO. This review summarizes recent developments and tries to put new HCC biomarkers in context with the WHOs reclassification. Furthermore it also addresses the group of tumors known as combined hepatocellular-cholangiocellular carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.